文献速递血栓与止血

血小板生成素受体激动剂用于妊娠期免疫性血小板减少症:多中心研究结果

Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study.
PubMed 文献 · Blood · 2020-01-01

该多中心观察性回顾性研究分析了15例妊娠期免疫性血小板减少症(ITP)患者(17次妊娠、18名新生儿)妊娠期超说明书使用艾曲泊帕(n=8)或罗米司亭(n=7)的安全性与疗效。中位暴露时间4.4周(范围1-39周),17次妊娠中10次(58%)为分娩准备而启动。除1例新生儿血小板增多症外,未观察到母体血栓栓塞事件或Tpo-RA相关胎儿/新生儿并发症;77%的病例获得治疗反应,其中70%的反应者联用ITP治疗。

要点

  • 妊娠期ITP患者超说明书使用Tpo-RAs,除1例新生儿血小板增多症外未观察到母体血栓栓塞或胎儿/新生儿并发症。
  • Tpo-RAs治疗反应率77%,其中70%的反应者联用其他ITP治疗;中位暴露时间4.4周(范围1-39周)。
  • 17次妊娠中10次(58%)为分娩准备而启动Tpo-RAs,4例为慢性难治性症状性ITP,3例妊娠开始时已在用艾曲泊帕。

核心结论

  • 基于这些初步发现,妊娠期严重和/或难治性ITP临时超说明书使用Tpo-RAs似乎对母体和新生儿均安全,且可能有益,尤其在分娩前。

研究设计与样本

  • 多中心观察性回顾性研究,分析15例妊娠期ITP患者(17次妊娠、18名新生儿),其中2例为继发性ITP;治疗药物为艾曲泊帕(n=8)或罗米司亭(n=7)。

主要发现

  • 中位Tpo-RA暴露时间为4.4周(范围1-39周)。
  • 17次妊娠中10次(58%)因分娩准备而启动Tpo-RAs,4例为慢性难治性症状性ITP,3例妊娠开始时已在用艾曲泊帕。
  • 除1例新生儿血小板增多症外,未观察到母体血栓栓塞事件或Tpo-RA相关胎儿/新生儿并发症。
  • 77%的病例获得Tpo-RAs治疗反应,其中70%的反应者联用其他ITP治疗。

临床怎么用

  • 作者认为,妊娠期严重和/或难治性ITP临时超说明书使用Tpo-RAs似乎对母体和新生儿均安全且可能有益,尤其在分娩前。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Management of immune thrombocytopenia (ITP) during pregnancy can be challenging because treatment choices are limited. Thrombopoietin receptor agonists (Tpo-RAs), which likely cross the placenta, are not recommended during pregnancy. To better assess the safety and efficacy of off-label use of Tpo-RAs during pregnancy, a multicenter observational and retrospective study was conducted. Results from 15 pregnant women with ITP (pregnancies, n = 17; neonates, n = 18) treated with either eltrombopag (n = 8) or romiplostim (n = 7) during pregnancy, including 2 patients with secondary ITP, were analyzed. Median time of Tpo-RA exposure during pregnancy was 4.4 weeks (range, 1-39 weeks); the indication for starting Tpo-RAs was preparation for delivery in 10 (58%) of 17 pregnancies, whereas 4 had chronic refractory symptomatic ITP and 3 were receiving eltrombopag when pregnancy started. Regarding safety, neither thromboembolic events among mothers nor Tpo-RA-related fetal or neonatal complications were observed, except for 1 case of neonatal thrombocytosis. Response to Tpo-RAs was achieved in 77% of cases, mostly in combination with concomitant ITP therapy (70% of responders). On the basis of these preliminary findings, temporary off-label use of Tpo-RAs for severe and/or refractory ITP during pregnancy seems safe for both mother and neonate and is likely to be helpful, especially before delivery.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Michel M, Ruggeri M, Gonzalez-Lopez TJ, et al. Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study. Blood. 2020. PMID: 32814348. doi:10.1182/blood.2020007594

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。